Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma

被引：1
|
作者：
Zimmermann, Julian [1 ]
Esser, E. [1 ]
Eter, N. [1 ]
Schuett, P. [2 ]
Uhlig, C. E. [1 ]
机构：
[1] Univ Klinikum Munster, Klin Augenheilkunde, Domagkstr 15, D-48149 Munster, Germany
[2] Onkol Gemeinschaftspraxis, Gutersloh, Germany
来源：
OPHTHALMOLOGIE | 2023年 / 120卷 / 07期
关键词：
D O I：
10.1007/s00347-022-01700-9
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：747 / 750
页数：4
相关论文
共 50 条
  • [21] FIRST USE EXPERIENCE OF BELANTAMAB MAFODOTIN IN MULTIPLE MYELOMA PATIENTS ON DIALYSIS
    Montesinos Lorena, Martinez
    Maria Magdalena, Anguita Arance
    Alonso Aranzazu, Alonso
    Moreno Maria, Jimenez
    Torres Alejandra, Segado
    de la Fuente Felipe, De Arriba
    HAEMATOLOGICA, 2021, 106 (10) : 138 - 139
  • [22] Impact of baseline ocular conditions on belantamab mafodotin-related corneal events in relapsed/refractory multiple myeloma
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Esposti, Simona Degli
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 65 - 66
  • [23] Multiple Myeloma Belantamab Mafodotin opens up new Treatment Perspective
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 427 - 428
  • [24] Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
    Offidani, Massimo
    Corvatta, Laura
    More, Sonia
    Olivieri, Attilio
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2401 - 2415
  • [25] Adverse ocular events related to belantamab mafodotin for treatment of multiple myeloma
    Lent-Schochet, Daniella
    Mokhashi, Nikita
    Vidyasagar, Nitin
    Farooq, Asim
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [26] Multiple Myeloma Belantamab Mafodotin opens up New Treatment Perspective
    Sankawa, Yuri
    ACTA HAEMATOLOGICA, 2021, 144 (05) : 592 - 593
  • [27] Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
    Abeykoon, Jithma P.
    Vaxman, Luliana
    Patel, Sanjay V.
    Kumar, Shaji
    Young, Kimberly S.
    Ailawadhi, Sikander
    Larsen, Jeremy T.
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Leung, Nelson
    Warsame, Rahma M.
    Hobbs, Miriam A.
    Fonder, Amie
    Hwa, Yi L.
    Bergsage, P. Leif
    Lacy, Martha Q.
    kumar, S. Vincent Raj
    Gertz, Morie A.
    Kapoor, Prashant
    BLOOD, 2021, 138
  • [28] Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
    David Gil-Sierra, Manuel
    Del Pilar Briceno-Casado, Maria
    Javier Julia-Luna, Francisco
    Dolores Martinez-Moya, Maria
    INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (05) : 373 - 376
  • [29] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
    Suvannasankha, Attaya
    Bahlis, Nizar
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Oriol, Albert
    Voorhees, Peter M.
    Alonso, Aranzazu A.
    Callander, Natalie S.
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Lamacchia, John
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne. C.
    Zhou, Xiangdong
    Gupta, Ira
    Opalinska, Joanna
    Nooka, Ajay K.
    CANCER, 2024, 130 (15) : 2629 - 2641
  • [30] Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma
    不详
    ONCOLOGY-NEW YORK, 2024, 38 (07):
12345